IL164552A0 - Binary or polynary targeting and uses thereof - Google Patents

Binary or polynary targeting and uses thereof

Info

Publication number
IL164552A0
IL164552A0 IL16455204A IL16455204A IL164552A0 IL 164552 A0 IL164552 A0 IL 164552A0 IL 16455204 A IL16455204 A IL 16455204A IL 16455204 A IL16455204 A IL 16455204A IL 164552 A0 IL164552 A0 IL 164552A0
Authority
IL
Israel
Prior art keywords
binary
polynary
targeting
polynary targeting
Prior art date
Application number
IL16455204A
Other languages
English (en)
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Publication of IL164552A0 publication Critical patent/IL164552A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/972—Modified antibody, e.g. hybrid, bifunctional

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Cell Biology (AREA)
  • Mathematical Physics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16455204A 2002-05-01 2004-10-13 Binary or polynary targeting and uses thereof IL164552A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37706702P 2002-05-01 2002-05-01
PCT/US2003/013637 WO2003093793A2 (en) 2002-05-01 2003-04-30 Binary or polynary targeting and uses thereof

Publications (1)

Publication Number Publication Date
IL164552A0 true IL164552A0 (en) 2005-12-18

Family

ID=29401442

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16455204A IL164552A0 (en) 2002-05-01 2004-10-13 Binary or polynary targeting and uses thereof

Country Status (7)

Country Link
US (1) US6867007B2 (de)
EP (1) EP1497466A4 (de)
JP (1) JP2005538049A (de)
AU (1) AU2003234327B2 (de)
CA (1) CA2482967A1 (de)
IL (1) IL164552A0 (de)
WO (1) WO2003093793A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287894B2 (en) * 2003-11-07 2009-01-29 Hepgenics Pty Ltd Binding assay components
JP2007510165A (ja) * 2003-11-07 2007-04-19 ヘプゲニクス ピーティワイ リミティッド 結合アッセイ成分
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1934867A2 (de) * 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
RU2009120007A (ru) * 2006-10-27 2010-12-10 Трастиз Оф Бостон Юниверсити (Us) Направленные конъюгаты с разделенными биомолекулами для лечения заболеваний, злокачественных образований и нарушений и способы их получения
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090068684A1 (en) * 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
EP2145902A3 (de) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP3023502A1 (de) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
US8735175B2 (en) 2011-03-18 2014-05-27 Chris D. Geddes Multicolor microwave-accelerated metal-enhanced fluorescence (M-MAMEF)
CN103543260A (zh) * 2013-07-30 2014-01-29 中国检验检疫科学研究院 一种基于磁分离-量子点免疫荧光传感检测生物大分子的方法及其试剂制备方法
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
EP3554544A4 (de) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. Anti-cub-haltige protein 1-(cdcp1)-antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
EP3612567B1 (de) 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1-antikörper und antikörper-wirkstoff-konjugate
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US4988617A (en) * 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
EP0787185A2 (de) * 1994-10-20 1997-08-06 MorphoSys AG Gezielte heterozusammensetzung von rekombinanten proteinen bei multifunktionalen komplexen
US6372427B1 (en) * 1995-04-12 2002-04-16 Hybridon, Inc. Cooperative oligonucleotides
US5981199A (en) * 1996-06-14 1999-11-09 Boehringer Mannheim Corporation Method for measuring antigen concentration
CA2196496A1 (en) * 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US20030103984A1 (en) * 1998-05-04 2003-06-05 Heinz Kohler Fusion proteins of biologically active peptides and antibodies
US6511809B2 (en) * 2000-06-13 2003-01-28 E. I. Du Pont De Nemours And Company Method for the detection of an analyte by means of a nucleic acid reporter
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins

Also Published As

Publication number Publication date
WO2003093793A2 (en) 2003-11-13
WO2003093793A3 (en) 2004-10-21
US20040033519A1 (en) 2004-02-19
EP1497466A4 (de) 2007-11-14
AU2003234327B2 (en) 2008-05-29
CA2482967A1 (en) 2003-11-13
AU2003234327A1 (en) 2003-11-17
US6867007B2 (en) 2005-03-15
JP2005538049A (ja) 2005-12-15
EP1497466A2 (de) 2005-01-19

Similar Documents

Publication Publication Date Title
IL164552A0 (en) Binary or polynary targeting and uses thereof
EP1539941A4 (de) Adzyme und deren verwendungen
ZA200603882B (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
IL175491A0 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
AU2003270341A8 (en) Modified asialo-interferons and uses thereof
AU2003256217A8 (en) New polymers and applications
EP1617807A4 (de) Substituierte 1,4-diazepine und ihre verwendungen
MXPA03001050A (es) Dispositivo desacelerador de rotacion y utilizacion del mismo.
PL375355A1 (en) Novel lipases and uses thereof
IL163868A0 (en) Hermiasterlin derivatives and uses thereof
PL377770A1 (pl) Podstawione benzoksazynony i ich zastosowanie
SI1551805T1 (sl) Substituirani gama-fenil-delta-laktami in njihova uporaba
GB0323954D0 (en) Block copolymer and use thereof
GB0217882D0 (en) Secure messaging
IL165112A0 (en) Variant integrinpolypeptides and thereof
AU2003214625A8 (en) Histone conjugates and uses thereof
GB0309064D0 (en) Modified peptides and their uses
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003228355A8 (en) Adipocytes and uses thereof
GB0318546D0 (en) Quinoxalinones and their use
AU2003299491A8 (en) Fagopyritol synthase genes and uses thereof
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
GB0228525D0 (en) Polymers and their use
EP1487547A4 (de) Mittel zur körperlichen wechselwirkung und seine verwandten verwendungen
EP1694845A4 (de) Antikarzinom-antikörper und verwendungen davon